Recent advancement in drugs of Alzheimer's disease

Alzheimer's disease (AD), a multifaceted neurological ailment that progresses over time, is the most common cause of dementia in older people. Intracellular neurofibrillary tangles and extracellular amyloidal protein deposits contribute to senile plaques on pathological level. AD symptoms vary depending stage disease. Depending severity cognitive impairment, classified as preclinical or presymptomatic, mild, dementia-stage. In addition, condition influenced by number risk factors, including advancing age, hereditary head injuries, vascular diseases, infections, environmental variables. There are currently only two types licenced medications treat AD: inhibitors cholinesterase enzyme such donepezil, rivastigmine, galantamine antagonists N-methyl d-aspartate (NMDA) memantine, both which effective treating do not cure prevent it.